Changeflow GovPing Pharma & Drug Safety Recombinant Haptoglobin HP Beta Chain Expressio...
Routine Notice Added Final

Recombinant Haptoglobin HP Beta Chain Expression System

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4334342A1 for CSL Behring AG and Universität Zürich covering an expression system for producing recombinant haptoglobin (HP) beta chain. The patent was published March 25, 2026, with inventors including Rebecca Butcher, Catherine Owcuzarek, Thomas Gentinetta, Dominik Schaer, and Michael Hugelshofer. This is a routine patent publication with no compliance obligations.

What changed

EPO published patent application EP4334342A1, a biotechnology patent covering an expression system for producing recombinant haptoglobin (HP) beta chain. The applicants are CSL Behring AG and Universität Zürich. Designated states cover all current EPO member states including Germany, France, UK, Italy, Spain, and others.

This patent publication does not impose any compliance deadlines or regulatory obligations on pharmaceutical companies or other entities. It represents intellectual property protection for a recombinant protein expression technology with potential therapeutic applications. No immediate action is required from compliance teams.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

EXPRESSION SYSTEM FOR PRODUCING A RECOMBINANT HAPTOGLOBIN (HP) BETA CHAIN

Publication EP4334342A1 Kind: A1 Mar 25, 2026

Applicants

CSL Behring AG, Universität Zürich

Inventors

BUTCHER, Rebecca, OWCZAREK, Catherine, GENTINETTA, Thomas, SCHAER, Dominik, HUGELSHOFER, Michael

IPC Classifications

C07K 14/805 20060101AFI20221111BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4334342A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Biotechnology Pharmaceutical Manufacturing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.